Phase II RCT in 200 patients with HR+/HER2− stage II–III breast cancer with Ki-67 ≥20%: 12 months of neoadjuvant letrozole plus abemaciclib achieved RCB 0–I in 13% vs 18% with 6 months of chemotherapy, failing to show similarity.
RCTn = 200
Martín et al. Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer